ArticleClinical practice and epidemiology in mental health : CP & EMH2019
Clinical and Neuropsychological Predictors of Methylphenidate Response in Children and Adolescents with ADHD: A Naturalistic Follow-up Study in a Spanish Sample.
Article in Clinical practice and epidemiology in mental health : CP & EMH, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Electrophysiological and Clinical Predictors of Methylphenidate, Guanfacine, and Combined Treatment Outcomes in Children With Attention-Deficit/Hyperactivity Disorder.Journal of the American Academy of Child and Adolescent Psychiatry · 2023Trial
- A Retrospective Study Examining Predictors of Treatment Response in Over 1,300 Children and Adolescents with Attention-deficit Hyperactivity Disorder.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2026Article
- Neuropsychological profile and clinical benefits of multimodal interventions in a child with ADHD, Generalized Anxiety Disorder, and Social (Pragmatic) Communication Disorder within the context of intellectual giftedness: a case report.Italian journal of pediatrics · 2026Article
- Dosing and Discontinuation of Methylphenidate Medication in Relation to Weight Status in Children and Adolescents.Paediatric drugs · 2026Article
- An explainable machine learning-based approach to predicting treatment response for neurofeedback in ADHD.Scientific reports · 2025Article
- Clinical response to a single-dose methylphenidate challenge is indicative of treatment response at two months in adults with ADHD.Translational psychiatry · 2025Article
- Predictors of Methylphenidate response in children and adolescents with ADHD: the role of sleep disturbances.European archives of psychiatry and clinical neuroscience · 2025Article
- Can response to ADHD medication be predicted?European child & adolescent psychiatry · 2025Observational
- Effects of methylphenidate on children with attention deficit hyperactivity disorder: a study using clinical and multimodal approaches including go/no-go task and functional near-infrared spectroscopy.Frontiers in pharmacology · 2025Article
- Article
- Poor response to methylphenidate is associated with a smaller dorsal attentive network in adult Attention-Deficit/Hyperactivity Disorder (ADHD).Translational psychiatry · 2023Article
- Comparing the Effect of Methylphenidate and Anodal tDCS on Inhibitory Control and Working-Memory in Children and Adolescents with Attention Deficit/Hyperactivity Disorder: A Study Protocol for a Randomized, within-Subject Trial.International journal of environmental research and public health · 2022Article
- Moderators and Other Predictors of Methylphenidate Response in Children and Adolescents with ADHD.International journal of environmental research and public health · 2022Article
- Disentangling the Association between ADHD and Alcohol Use Disorder in Individuals Suffering from Bipolar Disorder: A Systematic Review and Meta-Analysis.Brain sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMethylphenidate (MPH) is the most commonly used medication for Attention-Deficit/Hyperactivity Disorder (ADHD), but to date, there are neither consistent nor sufficient findings on conditions differentiating responsiveness to MPH response in ADHD.
objectiveTo develop a predictive model of MPH response, using a longitudinal and naturalistic follow-up study, in a Spanish sample of children and adolescents with ADHD.
methodsWe included all children and adolescents with ADHD treated with MPH in our outpatient Clinic (2005 to 2015), evaluated with the K-SADS interview. We collected ADHD-RS-IV.es and CGI-S scores at baseline and at follow up, and neuropsychological testing (WISC-IV, Continuous Performance Test (CPT-II) & Stroop). Clinical response was defined as >30% reduction from baseline of total ADHD-RS-IV.es score and CGI-S final score of 1 or 2 maintained for the previous 3 months.
resultsWe included 518 children and adolescents with ADHD, mean (SD) age of patients was 11.4 (3.3) years old; 79% male; 51.7% had no comorbidities; and 75.31% had clinical response to a mean MPH dose of 1.2 mg/kg/day. Lower ADHD-RS-IV.es scores, absence of comorbidities (oppositional-defiant symptoms, depressive symptoms and alcohol/cannabis use), fewer altered neuropsychological tests, higher total IQ and low commission errors in CPT-II, were significantly associated with a complete clinical response to methylphenidate treatment.
conclusionOppositional-defiant symptoms, depressive symptoms, and a higher number of impaired neuropsychological tests are associated with worse clinical response to methylphenidate. Other stimulants or non-stimulants treatment may be considered when these clinical and neuropsychological variables converged in the first clinical interview.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.